Enterome has entered a licensing, development and commercialisation agreement for its investigational drug candidate EB8018 with Takeda Pharmaceutical Company.
The drug is being developed to target liver diseases and gastrointestinal disorders such as Crohn’s disease.
Go deeper with GlobalData
Takeda has agreed to provide Enterome with an initial $50m investment followed by a further $640m if certain clinical development, regulatory and commercial milestones are reached.
The two companies have also agreed to co-develop and co-promote EB8018 in the US upon approval. Takeda will also hold an exclusive license to commercialise the product outside of the US, while Enterome will be eligible to receive royalties on the net sales generated in these territories.
Based in France, Enterome is a clinical-stage biotech company engaged in developing innovative therapies to treat microbiome-associated diseases, while Takeda is a pharmaceutical company based in Japan.
Galapagos and AbbVie have reached an agreement to restructure their existing partnership, which aims to develop cystic fibrosis (CF) drug candidates.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAbbVie will take over all of the companies’ CF-related programmes and pursue the development of a triple combination therapy for the disease. It will also be responsible for obtaining exclusive global rights for the current CF investigational drug candidate portfolio.
AbbVie has agreed to pay $45m upfront to Galapagos as part of the agreement. Galapagos will also receive up to $200m in additional milestone payments, following the completion of certain development, regulatory and commercial milestones.
Based in Belgium, Galapagos is a clinical-stage biotechnology company, while AbbVie is a US-based biopharmaceutical company.
AstraZeneca’s MedImmune division has reached an agreement with Innate Pharma to strengthen and expand their respective oncology portfolios.
Under the agreement, AstraZeneca will receive full oncology rights to monalizumab, a first-in-class humanised anti-NKG2A antibody developed in partnership with Innate Pharma.
It will also earn the option rights to antibody targeting CD39 IPH5201 and four pre-clinical molecules.
In addition, Innate will license the US and EU commercial rights to AstraZeneca’s recently US Food and Drug Administration (FDA) approved Lumoxiti for hairy cell leukaemia (HCL).
Based in the UK, AstraZeneca is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company, while Innate Pharma is a biotechnology company based in France.
Pfizer and Bain Capital have agreed to launch Cerevel Therapeutics, a new company aimed to develop new medicines to treat central nervous system (CNS) disorders.
The new company will benefit from Pfizer’s pre-commercial neuroscience assets and three clinical-stage and multiple pre-clinical compounds targeting various CNS diseases.
Based in the US, Pfizer is engaged in the development of pharmaceuticals, while Bain Capital, also based in the US, is a private investment firm.
